Retracing our steps: A review on autism research in children, its limitation and impending pharmacological...

Area of Science:

• Neurodevelopmental Disorders
• Autism Spectrum Disorder (ASD) Research
• Clinical Pharmacology

Background:

• Autism spectrum disorder (ASD) is a neurodevelopmental condition marked by communication, social interaction, and behavioral impairments.
• ASD presents heterogeneously, often co-occurring with ADHD, anxiety, depression, epilepsy, and metabolic or immune disorders.
• Current diagnostic methods lack objectivity, complicating tailored pharmacological management for core ASD symptoms.

Purpose of the Study:

• To highlight the critical need for objective, personalized diagnostic kits for ASD.
• To review current pharmacological management strategies for ASD-associated symptoms and comorbidities.
• To explore emerging therapeutic prospects for managing core ASD symptoms.

Main Methods:

• Literature review of current ASD diagnostic challenges.
• Analysis of approved pharmacological agents for ASD-related conditions.
• Exploration of novel therapeutic approaches for ASD.

Main Results:

• No approved medications directly treat core ASD symptoms; behavioral interventions are primary.
• Medications like aripiprazole, risperidone, methylphenidate, and melatonin manage associated symptoms (irritability, ADHD, sleep issues).
• The absence of objective diagnostics hinders personalized treatment development.

Conclusions:

• Objective diagnostic tools are imperative for individualizing ASD treatment strategies.
• Current pharmacotherapy targets associated symptoms, not core ASD deficits.
• Future research should focus on developing personalized treatments and diagnostics for ASD.